Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-VIII: Jivi in Severe Hemophilia A
NCT01580293Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2012
- Primary completion
- Jun 2014
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
A Phase 3 trial of damoctocog alfa pegol in hemophilia A, sponsored by Bayer. Started Apr 2012; status: completed.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT01580293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01580293.